Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal epithelial cells

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 79, Issue 6, 2008, Pages 223-231

  Yudina, Yulyana ^a   Parhamifar, Ladan ^a   Bengtsson, Astrid M L ^a   Juhas, Maria ^a   Sjölander, Anita ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

5 LO; COX 2; CysLT1R; CysLT2R; Intestinal epithelial cells; Leukotriene D4; LTC4S; LTD4; TNF

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; ICOSANOID; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE D4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOSYNTHESIS; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ARACHIDONATE 5-LIPOXYGENASE; CELL LINE; CELL LINE, TUMOR; CYCLOOXYGENASE 2; EICOSANOIDS; EPITHELIAL CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; INTESTINES; LEUKOTRIENE D4; RECEPTORS, LEUKOTRIENE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61549132288     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2008.09.024     Document Type: Article

References (40)

1. Romano M., and Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. Faseb J 17 (2003) 1986-1995
2. Vassalli P. The pathophysiology of tumor necrosis factors. Ann. Rev. Immunol. 10 (1992) 411-452
3. Levy B.D., Clish C.B., Schmidt B., Gronert K., and Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2 (2001) 612-619
4. Woszczek G., Pawliczak R., Qi H.Y., Nagineni S., Alsaaty S., Logun C., and Shelhamer J.H. Functional characterization of human cysteinyl leukotriene 1 receptor gene structure. J. Immunol. 175 (2005) 5152-5159
5. Samuelsson B. Prostaglandins, thromboxanes, and leukotrienes: formation and biological roles. Harvey Lect 75 (1979) 1-40
6. Luo M., Lee S., and Brock T.G. Leukotriene synthesis by epithelial cells. Histol. Histopathol. 18 (2003) 587-595
7. Dixon R.A., Diehl R.E., Opas E., Rands E., Vickers P.J., Evans J.F., Gillard J.W., and Miller D.K. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343 (1990) 282-284
8. Nicholson D.W., Ali A., Vaillancourt J.P., Calaycay J.R., Mumford R.A., Zamboni R.J., and Ford-Hutchinson A.W. Purification to homogeneity and the N-terminal sequence of human leukotriene C4 synthase: a homodimeric glutathione S-transferase composed of 18-kDa subunits. Proc. Natl. Acad. Sci. USA 90 (1993) 2015-2019
9. Carter B.Z., Shi Z.Z., Barrios R., and Lieberman M.W. gamma-glutamyl leukotrienase. a gamma-glutamyl transpeptidase gene family member, is expressed primarily in spleen, J. Biol. Chem. 273 (1998) 28277-28285
10. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
11. Urade Y., Watanabe K., and Hayaishi O. Prostaglandin D, E, and F synthases. J. Lipid. Mediat. Cell Signal 12 (1995) 257-273
12. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 68-69 (2002) 165-175
13. H aeggström J.Z., and Wetterholm A. Enzymes and receptors in the leukotriene cascade. Cell Mol. Life Sci. 59 (2002) 742-753
14. Werz O., and Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol. Ther. 112 (2006) 701-718
15. Wang D., and Dubois R.N. Prostaglandins and cancer. Gut 55 (2006) 115-122
16. Evans J.F. The cysteinyl leukotriene receptors. Prostaglandins Leukot. Essent. Fatty Acids 69 (2003) 117-122
17. Magnusson C., Ehrnström R., Olsen J., and Sjölander A. An Increased Expression of Cysteinyl Leukotriene 2 Receptor in Colorectal Adenocarcinomas Correlates with High Differentiation. Cancer Res 67 (2007) 9190-9198
18. Capra V. Molecular and functional aspects of human cysteinyl leukotriene receptors. Pharmacol. Res. 50 (2004) 1-11
19. Ekbom A., Helmick C., Zack M., and Adami H.O. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 323 (1990) 1228-1233
20. Casellas i Jorda F. TNF-alpha inhibitors in inflammatory bowel disease. Med. Clin. (Barc) 123 (2004) 627-634
21. Rutgeerts P., Van Assche G., and Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease-seven years on. Aliment. Pharmacol. Ther. 23 (2006) 451-463
22. Sheng H., Shao J., Dixon D.A., Williams C.S., Prescott S.M., DuBois R.N., and Beauchamp R.D. Transforming growth factor-beta1 enhances Ha-Ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem. 275 (2000) 6628-6635
23. Dixon D.A., Tolley N.D., King P.H., Nabors L.B., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest. 108 (2001) 1657-1665
24. Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S., and Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531 (2002) 278-284
25. 1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124 (2003) 57-70
26. Itzkowitz S.H., and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287 (2004) G7-17
27. Wardle T.D., Hall L., and Turnberg L.A. Platelet activating factor: release from colonic mucosa in patients with ulcerative colitis and its effect on colonic secretion. Gut 38 (1996) 355-361
28. 4 antagonist on colonic damage induced by intracolonic administration of trinitrobenzene sulfonic acid in rats. J. Gastroenterol. 30 (1995) 34-40
29. 4 mediates survival and proliferation via separate but parallel pathways in the human intestinal Epithelial cell line Int 407. J. Biol. Chem. 278 (2003) 45577-45585
30. Gross V., Andus T., Leser H.G., Roth M., and Scholmerich J. Inflammatory mediators in chronic inflammatory bowel diseases. Klin. Wochenschr. 69 (1991) 981-987
31. 4 metabolism in colonic mucosa with inflammatory bowel disease. Scand. J. Gastroenterol. 30 (1995) 44-49
32. Singer II, Kawka D.W., Schloemann S., Tessner T., Riehl T., and Stenson W.F. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115 (1998) 297-306
33. Hendel J., and Nielsen O.H. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am. J. Gastroenterol. 92 (1997) 1170-1173
34. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
35. Sharon P., Ligumsky M., Rachmilewitz D., and Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine,. Gastroenterology 75 (1978) 638-640
36. Yoshimatsu K., Golijanin D., Paty P.B., Soslow R.A., Jakobsson P.J., DeLellis R.A., Subbaramaiah K., and Dannenberg A.J. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res. 7 (2001) 3971-3976
37. 2 and upregulation of alpha2beta1-integrin. Exp. Cell. Res. 289 (2003) 342-351
38. 4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. J. Biol. Chem. 281 (2006) 6776-6784
39. 4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J. Biol. Chem. 280 (2005) 13538-13544
40. 1 receptors and down-modulate cysteinyl leukotriene-dependent mitogenic responses of mast cells. Blood 110 (2007) 3263-3270